2021
FG001 was well tolerated, and light was detected in all patients at the fifth dose level (16mg) administered in the evening before...
The ongoing clinical phase I/II trial with FG001 is designed as a two-phase trial, where the first phase aims to identify the optimal...
30 June, 2021
FluoGuide enters agreement with Swedish university hospital for the second phase of the ongoing FG001 clinical trial
The ongoing clinical phase I/II trial with FG001 is designed as a two-phase trial, where the first phase aims to identify the optimal...
The agenda for the general meeting was as follows: Following was decided on the extraordinary General Meeting: Re 1: Election of...
17 June, 2021
New article reveals promising results of using FluoGuide’s FG002 technology in guiding surgical removal of cancer
The preclinical study demonstrated FG002 to light up cancer with several promising features holding great promises for the use of guiding...
To the shareholders of FluoGuide A/S The board of directors proposes the election of Mat Thorén as new board member. Mats Thorén...
1 June, 2021
FluoGuide A/S - Flagging message
FluoGuide A/S (“FluoGuide” or “the Company”) hereby announce that Arbejdernes Landsbank has informed the Company...
Today, the Board of Directors of FluoGuide has exercised its authorization to issue new warrants by issuing 272,700 warrants to employees...
oGuide announc *) Result per share (DKK per share): Operating result divided by the average number of shares during the period. The...